quarter and our Good recent results. we again provide financial overview you of for XXXX us taking you, Andrea. thank join as Thank the highlights today discuss and business fourth afternoon everyone, once time to an
Joining our me is Norman officer. for the call Dr. and LaFrance, today Officer Medical Mr. our Chief Chief Andrew Sims, Financial
I'll extremely begin us call reviewing with XXXX. in pleased joining high for and financials Andrew XXXX and a the our review accomplishments our to be by LaFrance Q&A. was will I Dr. At then level,
year, our sheet, Going materially of almost exceeded for to continued a expanded approach set achieved will cash but similar significant of as discuss. very same we our the ourselves Andrew year all we and level prior development cash we time, balance we year, conservative into ending managing the the goals with or a them. availability the At some to
regulatory Let on focusing begin development, and drug me milestones. related clinical by activities
was in a that whole one wind you First recurrent funded I phase over with at and a year by the glioblastoma year that clock ask that we single which clinical NIH. in the only was essence single for program That our in a back part drug, ago. recall development a XXXX ended XXXRNL active was development active large of That time. program clinical the
investigational Leptomeningeal. drug and Rhenium XXXRNL-BAM clinical XXX Alginate the called obisbemeda, active GBM obisbemeda, the year (XXXRe) our call to recurrent drug, end or we XXXRNL forward of Rhenium other (XXXRe) and one with Rhenium two the for two we we Microsphere obisbemeda, regarding now for ended have investigation programs candidates, it Fast ongoing, Rhenium as Bioabsorbable formerly XXXX,
of terms this glioblastoma program. In substantially we expanded in XXXX,
from to we phase phase Specifically, two. advanced one
higher with the us into negotiated dose FDA continuing first for tumors are dose that explore have and happen retreating allowing manufactured larger phase an larger We trial protocol tumors now and patient phase the enrolled re-treatment in move two volumes. expansion to We two. We the one active GMP we dose drug escalation to phase a the and for treatment. after to continue FDA with patients first to occur
for phase through to in match this enrollment combination to essentially by pluses should required approximately two GBM For to advance a XXX patients. that Leptomeningeal third specifically and an fund obtained in this with order enrolling $XX.X program. secret, in the we million That move stage the with that one, and grant of disease, we this one program we program be program sufficient phase from preclinical co-lead successfully as program funding
For were we pediatric did trial in discussions brain not significant trial, with we for the FDA initiate patient RADIOPHARMACEUTICAL required pediatric the make did because first this in year that the cancer, of this progress. while calendar
nature the additional submit of IND we which data, our cancers. design, adult reviewers require accepted three FDA the to have still of soon. on some protocol request rounds pediatric after but interactions relatively and plan for Specifically FDA brain clinical
manufactured And of that -- that last successfully then used Alabama and drug. the from in the Our second we human then that then XVIVO preclinical We model, pre-IND successfully organ year. drug during in XXXX, and information plus the packaged submitted the manufacturing we in drug, to that confirming perfusion FDA. during feasibility to technology XXXR was internally to drug licensed early transferred XXXX academia, in successfully
terms was company's development. the transformative of in achieved a So in XXXX big picture milestones year
programs, clinical data XXXX, presented Cancer. we readouts GBM in our lead in two and important Additionally, Leptomeningeal
the from in Society PI. phase Results glioblastoma for by the company's Florida trial Neuro-Oncology meeting In was - the First SNO ReSPECT patients XX that one in The a phase GBM GBM one presented of radiation. to XXXX. with gray Rhenium current At escalation single trial. time, That's trial across at a for November, in to the achieving about phase, on the dose tumors cohorts of escalation administered external to using dose XXX seven dose radiation compared average obisbemeda received up absorb total tumor. XX recurrent beam does delivered
significant Rhenium is the in for dose to survival treated between positive both overall one can administered and tumor signal data that volume of be showed the strength tumor trial statistically in volume, phase and trial. there's the unusually the and obisbemeda absorbed our safely correlation, radiation The a but percent a
every, a we death. hundred that The risk every in percent. for the dose increase volume also in more the the of every radiation lower of max X% XX% that treated increase to a with of absorbed decrease the absorbed the risk the XXX specifically and found death, up to correlated tumor, dose the in in correlated tumor increase in about every And a gray
effective Obviously, that was dose patients There potentially the overall administration no safe of statistically limiting safety the is favorable. The study very the a study when in concluded poor feasible, X.X% by is that increasing a decrease Rhenium were to delivery and of radiation was reported, and survival single toxicities death, with highly tumor. glioma in prognosis convection of significant. enhanced in profile with delivered that dose overall obisbemeda con therapeutic associated the recurrent is the risk and
XX.X initiated QX evaluating and XX over GBM cohorts, delivering six Based small we CCS X.X two for our that treatment millicuries were XXXX, phase in obisbemeda inject phase Rhenium the patients of tumors, are less. XX% tumors the using eight cohort the in recurrent on the milliliters And in a dose, of we with about or media expansion trial data from the essentially treated. patients which trial, and dose sized a for of is therapeutic latter dose one that's and
National intend XX additional in to from to months or patients that Cancer an XX by to enroll the medium That less. enroll supported be with approximately Institute. This trial in we up small and phase size trial an continues tumors we to two will award approximately,
authorized overall six under While safety a the beyond survival survival response, and we following The survival the we endpoint secondary event-free single sites plan rate, authorized endpoint is faster trial as five and partial NIH, the administration, an to objective agreed have to primary with the five expand which enrollment. the PI with the to the number NIH is of reminder response sites progression-free SAEs, will and at months. FDA assess we endpoints tolerability facilitate
to exploration be the focus happen number clinical also future ongoing administration key increasing of after above, and development further the dose and inform the by doses the to occur trial. to mentioned registrational dose as of patients and investigation GBM of increasing areas single design program Also, will a also who
trial As designations discussed and registrational and on pivotal. orphan in the arm our use data fast speed agreed including company control of previously, to the and future FDA track the potential to external the by the facilitated hold as design, enrollment meetings augment
line and let advanced Rhenium you the move study central LM trial of our safety Metastases or development may escalation of nervous LM, to cancers system, called one Now dose rated multi-center leptins. associated know, on Leptomeningeal as is also fluid phase structures LM with me dose a complication infiltrate efficacy two the obisbemeda. that program. The the
FDA improved the are with affected local twice often with are about includes and orally, administered LM chemotherapy with treatment substantially into approved per intravenously, CSF affected of either patients cancer care year or it's that growing to and the, Standard the LM that radiation that It therapy incidence there underdiagnosed. and no so and the space. directly there a therapies given XXX,XXX happens beam external potentially sites, is week
Systemically almost injuries. preventing barrier the never to administered work the blood-brain therapies leptin of because access
the the to that was meeting back bipa that at XX feasible, measured we dosages two between data of hours meeting following award that studied treatment funding in administration cohorts single in the So in XX% two patients going showing across of the vial early from treatment terms demonstrated XX% was the count also CSF with prevented and cell trial tolerated one LM from November, of with and Research well time to XXXX. presented a trial a back one development count cell for patients that at began tumor that phase that in in SNO funding again was safe AM ReSPECT Texas million in that and Secret the Institute received research of of quarter reduction product CSF. The fourth the $XX.X tumor after Prevention decreased Cancer by we the
including the program of important of majority and cover cost, enrolled non-dilutive development XXX for three the the award LM patients up source mentioned, an that's for years, to funding As over funding. this will
six trial. completed patients been enrollment That sheet. that In steps material the of early strengthens two now balance company's LM regarding cohort with treated trial, in XXXX, and we the have next
Board in we'll Monitoring to Following phase in which the March, Safety DSMB, in one and of A complete patients enrollment review, that quarter, the part the is the will perhaps anticipated portion we soon, nine be next total. that Data anticipate be
determine one second Thereafter, part B dose expansion the with for in XXXX. that to half trial the we B part initiate we of FDA then the exact meeting plan the and a phase plans trial, expect that
initial XXXX. in also expect second to from the the part data We of one presented be phase also half A
partnerships resilient products. GMP As building I the enable that made of our supply even through third have development robust and in commercialization in our in progress we our chain 'XX call November, future strategic our quarter, significant mentioned on more making manufacturer a and potential
updated for clinical safety partners end Hospital supply Based brain C application study brain submitted be that's ongoing the extensive and be with the at as tumors. extensive cancer, last three an of institution, two, Children's academic submit in Rhenium obisbemeda chain with Northwestern Chicago. conjunction pediatric or for finding in lead new of current to trials pediatric now planned phase lm fully positioned pediatric ReSPECT our dose cancer. what are key and drug obisbemeda GBM, expect will year, PBC phase in patients Our place called will brain one in It any to on Rhenium supply we previously, of GMP and Lurie f and University investigational for efficacy
to define a it XXXR novel on pursuing specifically the radio in Furthermore, or for its designation this our FDA terms appropriate embolic Microparticle to the development the Technology in app in designation performing request most regulatory two product be drug process device Alabama, we for activities. in regulatory we investigational developmental regarding path, parallel feedback are of based objectives. required the Finally, recently success should whether licensed regarding
is, Regardless for decades, whatever in the ultimately drug. the designation which our some bio-restorable that products the are market, competing designation the been legacy market as embolic have ultimate are that ultimate its on the nature the radio two view supports [indiscernible] of of permanently over that indwelling despite regulatory it's that cases products fact our a
guidance ultimate that irrespective their this seek developing to determination, liver company determination we other FDA reasonably proceed the plans initially for on can as on fire with as regulatory collaborate those generation with parallel the at ultimate to next on the mentioned the a technology activities BAM reservable, calls, and first development we'll Nonetheless in radial previously embolic therapy do cancer. of focus
So to with the Andrew that Sims, review summary, Andrew? officer, I'll who over financials. financial chief our turn the floor will
